can you explain how the regulatory pathway for biogenerics helps. I think the new regulations hurt companies pursuing bio generics. The fda is asking for safety and efficacy studies. How do you recruit patients on a drug for a trial where the endpoint is that the efficacy is the same.
Market Data 
Markets 
AI
